Subtype
Urinary System Carcinoma
CI-CAN-00004182Explore in graph →
670 active trials25 approved drugs87 evidence items
- NCIt
- C181197
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00004182Explore in graph →
Clinical trials
2,394 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (391)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01767636 | Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer | completed | Phase 2 | 38 | Mayo ClinicOTHER | 1 | Mar 3, 2025 | clinicaltrials |
| NCT02567409 | Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer | completed | Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT01130519 |
| A Phase II Study of Bevacizumab and Erlotinib in Subjects With Advanced Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) or Sporadic Papillary Renal Cell Cancer |
| completed |
| Phase 2 |
| 83 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Feb 21, 2025 |
| clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT04666688 | LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 44 | PureTechINDUSTRY | 1 | Feb 12, 2025 | clinicaltrials |
| NCT03240016 | Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer(ABLE) | completed | Phase 2 | 36 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
| NCT01884961 | Radiotherapy As an Immunological Booster in Patients with Metastatic Melanoma or Renal Cell Carcinoma Treated with High-dose Interleukin-2(IL2HD) | completed | Phase 2 | 46 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02761057 | Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed | completed | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 2 | Jan 13, 2025 | clinicaltrials |
| NCT04068831 | Talazoparib and Avelumab in Participants With Metastatic Renal Cell Carcinoma | completed | Phase 2 | 18 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT01291420 | Dendritic Cell Vaccination for Patients with Solid Tumors | completed | Phase 1 / Phase 2 | 48 | University Hospital, AntwerpOTHER | 1 | Dec 9, 2024 | clinicaltrials |
| NCT03534804 | Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma(PemCab) | completed | Phase 2 | 37 | University of UtahOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT03015740 | Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer | completed | Phase 1 / Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT02639182 | A Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma | completed | Phase 2 | 133 | Astellas Pharma Global Development, Inc.INDUSTRY | 2 | Nov 18, 2024 | clinicaltrials |
| NCT03658304 | Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma | completed | Phase 2 | 29 | University of FloridaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT02819596 | MEDI4736 Combinations in Metastatic Renal Cell Carcinoma(CALYPSO) | completed | Phase 2 | 69 | Queen Mary University of LondonOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT03109015 | Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing(ASSET) | completed | Phase 2 | 7 | Duke UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT02667886 | Trial of X4P-001 in Participants With Advanced Renal Cell Carcinoma | completed | Phase 1 / Phase 2 | 74 | X4 PharmaceuticalsINDUSTRY | 2 | Oct 3, 2024 | clinicaltrials |
| NCT03108066 | MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) | completed | Phase 2 | 4 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Sep 24, 2024 | clinicaltrials |
| NCT05485896 | Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC | completed | Phase 2 | 23 | Tianjin Medical University Second HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT00554515 | The High-Dose Aldesleukin (IL-2) "Select" Trial for Patients With Metastatic Renal Cell Carcinoma(SELECT) | completed | Phase 2 | 123 | Beth Israel Deaconess Medical CenterOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03557918 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | completed | Phase 2 | 26 | Matthew GalskyOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03097328 | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Bradley A. McGregor, MDOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT03126331 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | completed | Phase 2 | 26 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03339843 | Multiorgan Metabolic Imaging Response Assessment of Abemaciclib(MiMe-A) | completed | Phase 2 | 85 | Jules Bordet InstituteOTHER | 2 | Mar 15, 2024 | clinicaltrials |
| NCT03665285 | A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors | completed | Phase 1 / Phase 2 | 109 | NextCure, Inc.INDUSTRY | 1 | Mar 8, 2024 | clinicaltrials |
| NCT00019396 | flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT00019539 | Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer | completed | Phase 2 | — | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2024 | clinicaltrials |
| NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 269 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT03511391 | CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors(CHEERS) | completed | Phase 2 | 99 | University Hospital, GhentOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04496219 | Acupuncture for the Treatment of Intravesical BCG-Related Adverse Events in High-Risk Non-muscle Invasive Bladder Cancer | completed | Phase 2 | 45 | Fred Hutchinson Cancer CenterOTHER | 1 | Jan 2, 2024 | clinicaltrials |
| NCT04073602 | A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 2 | 19 | RemeGen Co., Ltd.INDUSTRY | 1 | Dec 18, 2023 | clinicaltrials |
| NCT02795156 | Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations | completed | Phase 2 | 100 | SCRI Development Innovations, LLCOTHER | 1 | Dec 5, 2023 | clinicaltrials |
| NCT03809013 | A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer | completed | Phase 2 | 64 | RemeGen Co., Ltd.INDUSTRY | 1 | Nov 27, 2023 | clinicaltrials |
| NCT02599324 | Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors | completed | Phase 1 / Phase 2 | 263 | Pharmacyclics LLC.INDUSTRY | 4 | Nov 18, 2023 | clinicaltrials |
| NCT02527434 | Study of Tremelimumab in Patients With Advanced Solid Tumors | completed | Phase 2 | 64 | AstraZenecaINDUSTRY | 5 | Nov 15, 2023 | clinicaltrials |
| NCT04045613 | Derazantinib and Atezolizumab in Patients With Urothelial Cancer(FIDES-02) | completed | Phase 1 / Phase 2 | 95 | Basilea PharmaceuticaINDUSTRY | 14 | Oct 13, 2023 | clinicaltrials |
| NCT03680521 | Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma | completed | Phase 2 | 25 | Mirati Therapeutics Inc.INDUSTRY | 1 | Oct 4, 2023 | clinicaltrials |
| NCT01517243 | Phase II Study of Alternating Sunitinib and Temsirolimus | completed | Phase 2 | 37 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 21, 2023 | clinicaltrials |
| NCT03207347 | A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) | completed | Phase 2 | 37 | University of FloridaOTHER | 1 | Sep 15, 2023 | clinicaltrials |
| NCT03639714 | A Study of a Personalized Neoantigen Cancer Vaccine | completed | Phase 1 / Phase 2 | 29 | Gritstone bio, Inc.INDUSTRY | 2 | Sep 13, 2023 | clinicaltrials |
| NCT03200717 | Study of Efficacy, Safety, and Quality of Life of Pazopanib in Patients With Advanced and/or Metastatic Renal Cell Carcinoma After Prior Checkpoint Inhibitor Treatment(IO-PAZ) | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 21, 2023 | clinicaltrials |
| NCT03636256 | Evaluation of NanoDoce® in Participants With Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 36 | NanOlogy, LLCINDUSTRY | 1 | Aug 14, 2023 | clinicaltrials |
| NCT03421652 | Nivolumab and RT in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemo | completed | Phase 2 | 20 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Aug 4, 2023 | clinicaltrials |
| NCT02855203 | Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours(RAPPORT) | completed | Phase 1 / Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT01689766 | Study Using FolateScan to Identify Subjects With Folate Receptor-Positive Metastatic Renal Cell Carcinoma | completed | Phase 2 | 150 | EndocyteINDUSTRY | 1 | Jul 25, 2023 | clinicaltrials |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | completed | Phase 2 | 121 | Incyte CorporationINDUSTRY | 8 | Jul 21, 2023 | clinicaltrials |
| NCT00068393 | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma | completed | Phase 2 | 39 | Eastern Cooperative Oncology GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
Data updated 22 days agoSource updated Mar 3, 2025source: clinicaltrials